E Shyong Tai1, Jose M Ordovas. 1. Department of Endocrinology, Singapore General Hospital, Department of Medicine and Center for Molecular Epidemiology, National University of Singapore, Singapore.
Abstract
PURPOSE OF REVIEW: We have examined the evidence from recent human studies examining the role of apolipoprotein A-V in triglyceride-rich lipoprotein metabolism and cardiovascular disease risk. Special emphasis was placed on the evidence emerging from the association between genetic variability at the apolipoprotein A5 locus, lipid phenotypes and disease outcomes. Moreover, we address recent reports evaluating apolipoprotein A5 gene-environment interactions in relation to cardiovascular disease and its common risk factors. RECENT FINDINGS: Several genetic association studies have continued to strengthen the position of APOA5 as a major gene that is involved in triglyceride metabolism and modulated by dietary factors and pharmacological therapies. Moreover, genetic variants at this locus have been significantly associated with both coronary disease and stroke risks. SUMMARY: Apolipoprotein A-V has an important role in lipid metabolism, specifically for triglyceride-rich lipoproteins. However, its mechanism of action is still poorly understood. Clinical significance at present comes largely from genetic studies showing a consistent association with plasma triglyceride concentrations. Moreover, the effects of common genetic variants on triglyceride concentrations and disease risk are further modulated by other factors such as diet, pharmacological interventions and BMI. Therefore, these genetic variants could be potentially used to predict cardiovascular disease risk and individualize therapeutic options to decrease cardiovascular disease risk.
PURPOSE OF REVIEW: We have examined the evidence from recent human studies examining the role of apolipoprotein A-V in triglyceride-rich lipoprotein metabolism and cardiovascular disease risk. Special emphasis was placed on the evidence emerging from the association between genetic variability at the apolipoprotein A5 locus, lipid phenotypes and disease outcomes. Moreover, we address recent reports evaluating apolipoprotein A5 gene-environment interactions in relation to cardiovascular disease and its common risk factors. RECENT FINDINGS: Several genetic association studies have continued to strengthen the position of APOA5 as a major gene that is involved in triglyceride metabolism and modulated by dietary factors and pharmacological therapies. Moreover, genetic variants at this locus have been significantly associated with both coronary disease and stroke risks. SUMMARY:Apolipoprotein A-V has an important role in lipid metabolism, specifically for triglyceride-rich lipoproteins. However, its mechanism of action is still poorly understood. Clinical significance at present comes largely from genetic studies showing a consistent association with plasma triglyceride concentrations. Moreover, the effects of common genetic variants on triglyceride concentrations and disease risk are further modulated by other factors such as diet, pharmacological interventions and BMI. Therefore, these genetic variants could be potentially used to predict cardiovascular disease risk and individualize therapeutic options to decrease cardiovascular disease risk.
Authors: Ji Young Kim; Oh Yoen Kim; Soo Jeong Koh; Yangsoo Jang; Sung-Seob Yun; Jose M Ordovas; Jong Ho Lee Journal: J Am Coll Nutr Date: 2006-08 Impact factor: 3.169
Authors: Nicholas Tentolouris; Andreas Stylianou; Evangelia Lourida; Despoina Perrea; Despoina Kyriaki; Eleni C Papavasiliou; Alexandros D Tselepis; Nicholas Katsilambros Journal: J Lipid Res Date: 2006-10-03 Impact factor: 5.922
Authors: Piya Lahiry; Matthew R Ban; Rebecca L Pollex; Ross D Feldman; Cynthia G Sawyez; Murray W Huff; T Kue Young; Peter Bjerregaard; Robert A Hegele Journal: Int J Circumpolar Health Date: 2007-12 Impact factor: 1.228
Authors: Sekar Kathiresan; Olle Melander; Candace Guiducci; Aarti Surti; Noël P Burtt; Mark J Rieder; Gregory M Cooper; Charlotta Roos; Benjamin F Voight; Aki S Havulinna; Björn Wahlstrand; Thomas Hedner; Dolores Corella; E Shyong Tai; Jose M Ordovas; Göran Berglund; Erkki Vartiainen; Pekka Jousilahti; Bo Hedblad; Marja-Riitta Taskinen; Christopher Newton-Cheh; Veikko Salomaa; Leena Peltonen; Leif Groop; David M Altshuler; Marju Orho-Melander Journal: Nat Genet Date: 2008-01-13 Impact factor: 38.330
Authors: Brian H Shirts; Michael T Howard; Sandra J Hasstedt; M Nazeem Nanjee; Stacey Knight; John F Carlquist; Jeffrey L Anderson; Paul N Hopkins; Steven C Hunt Journal: Atherosclerosis Date: 2012-03-01 Impact factor: 5.162
Authors: Carmen Sánchez-Moreno; Jose M Ordovás; Caren E Smith; Juan C Baraza; Yu-Chi Lee; Marta Garaulet Journal: J Nutr Date: 2011-01-05 Impact factor: 4.798
Authors: D D V Brito; A P Fernandes; K B Gomes; F F Coelho; N G Cruz; A P Sabino; J E Cardoso; P P Figueiredo-Filho; R Diamante; C R Norton; M O Sousa Journal: Mol Biol Rep Date: 2010-12-04 Impact factor: 2.316
Authors: Elena Mendoza-Barberá; Josep Julve; Stefan K Nilsson; Aivar Lookene; Jesús M Martín-Campos; Rosa Roig; Alfonso M Lechuga-Sancho; John H Sloan; Pablo Fuentes-Prior; Francisco Blanco-Vaca Journal: J Lipid Res Date: 2013-01-10 Impact factor: 5.922